UK drug giants in the spotlight as part of latest sector review
The UK's two big drugmakers came under the spotlight in Berenberg's latest review of the pharmaceuticals sector. AstraZeneca PLC (LSE:AZN) gets a clear thumbs-up with a 'buy' rating and price targe...
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
The U.K.-based AstraZeneca Plc AZN paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
The company has shelved plans for a research facility in Cambridge, a move that follows the drugmaker in January scrapping an investment in Liverpool.
AstraZeneca faces pivotal test as spotlight shifts to Baxdrostat's 24-hour data
AstraZeneca PLC (LSE:AZN) may have caught the market's attention last weekend with promising data on its experimental blood pressure treatment, but the follow-up analysis suggests the story is far ...
AstraZeneca's Baxdrostat makes its case
Among the noise of tariffs, drug pricing reforms, and shifting investor sentiment, AstraZeneca PLC (LSE:AZN) has quietly delivered a clear result: its experimental blood pressure treatment, baxdros...
AstraZeneca to seek approval for blood pressure drug by year-end
AstraZeneca plans to file for regulatory approval of its experimental blood pressure treatment before the end of the year, a senior company executive said, about a product seen as key to the drugma...
AstraZeneca: Great Portfolio, But Not A Great Price
AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and Ulto...
Ex-dividend day weighs heavily on the FTSE this week
Thursday is ex-dividend day in London and this week there was a heavyweight billing that knocked the FTSE 100 sideways, including companies such as AstraZeneca PLC (LSE:AZN), NatWest Group PLC (LSE...
AstraZeneca gets clean bill of health from leading investment bank
AstraZeneca PLC (LSE:AZN) shares have caught the attention of UBS, which reiterated its 'buy' rating and raised its price target to 14,200p, implying over 27% upside from the current level, after a...
AstraZeneca CEO: Medical innovation in China is surging
"What we have seen in China is really, a substantial return of scientists from the US, but also from the UK and elsewhere, but not because of policy, simply because they could see opportunities in ...
AstraZeneca gets £3.3bn lift after upbeat results and steady outlook
AstraZeneca PLC (LSE:AZN) saw £3.3 billion added to its market value after delivering a strong set of half-year results and confirming its guidance for 2025. The group reported second-quarter reven...
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
AZN's second-quarter revenues beat on strong drug sales across Oncology and CVRM despite in-line earnings.
AstraZeneca Stock Rises as US, Cancer Drug Growth Lifts Q2 Results
AstraZeneca (AZN) shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates on strong U.S. growth and demand for its cancer drugs.
AstraZeneca maintains outlook as pipeline delivers strong late-stage results
AstraZeneca PLC (LSE:AZN) has reiterated its full-year guidance for 2025, following a robust set of results for the second quarter and first half, and pointed to a series of significant late-stage ...
AstraZeneca beats second-quarter profit expectations, maintains outlook
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures an...
Related Companies